EUCTR2021-006812-10-IT进行中（未招募）1 期
Phase 1/2 Study of BDC 1001 as a Single Agent and in Combination with Nivolumab in Patients with Advanced HER2-Expressing Solid Tumors. - N/A
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 655
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.For P.1 and P.2:
- •a.Pt has an advanced solid tumor for which approved therapies have been exhausted or for which the Investigator considers the patient ineligible or intolerant of other forms of treatment
- •bTumor has documented HER2 expression. At least 1 of the first 3 patients evaluated for DLT in Cohort M2 and all subsequent cohorts in Part 1 requires documented HER2 protein expression in tumor tissue.
- •2.For Part 3 and Part 4:
- •a.Patient has an advanced solid tumor for which approved therapies have been exhausted or for which the Investigator considers the patient ineligible or intolerant of other forms of treatment and also has the
- •breast cancer HER2+ cohorts (3A and 4A):
- •1)Has histologically documented advanced or metastatic HER2+ breast cancer
- •2)Has received at least 2 prior treatment regimens with anti-HER2 agents
- •For GE cancer cohorts (3B and 4B):
- •1)Has histologically documented advanced or metastatic HER2+ GE cancer
- •2)Has prior treatment with trastuzumab based therapy For other tumor types cohorts (3C and 4C):
- •1)Has histologically documented advanced or metastatic HER2+ cancer other than CRC, endometrial cancer, GE cancer, or breast cancer
- •For HER2-low breast cancer cohorts (3D and 4D)
- •1)Has histologically documented advanced or metastatic breast cancer
- •2)HER2-low tumors are defined as IHC2+ and negative or equivocal gene amplification
- •For CRC with HER2+ tumor cohorts (3E and 4E)
- •1)Has histologically documented advanced or metastatic HER2+ CRC
- •For endometrial cancer with HER2+ tumor cohorts (3F and 4F)
- •1)Has histologically documented advanced or metastatic HER2+ endometrial cancer
- •3.Age greater than or equal to 18 years old
- •4.Mentally competent and able to understand and sign the informed consent form
- •5.Eastern Cooperative Oncology Group performance status of 0 or 1
- •6.Expected life expectancy of greater than 12 weeks.
- •7.Has LVEF = 50% by either echocardiography or multiple-gated acquisition within 28 days before C1D1
- •8.Has disease that is measurable by (RECIST) v1.1
- •9.Has tumor tissue (archival or collected prior to the study start) available for exploratory biomarker evaluation. A representative formalin-fixed paraffin-embedded (FFPE) tumor specimen in paraffin block (preferred) or at least 15 unstained, freshly cut, serial sections (on slides) from an FFPE tumor specimen is required for participation in this study. The specimen must be accompanied by the associated pathology report.
- •a.If archival tissue is either insufficient or unavailable, the patient may still be eligible upon discussion with the Medical Monitor if the patient is willing to consent to and undergo a pretreatment tumor biopsy
- •collection.
- •b.The following specimen types are acceptable: resections, core needle biopsies, excisional, incisional, punch, or forceps biopsies. For core needle biopsy specimens, preferably, at least 3 cores embedded in a
- •single paraffin block should be submitted for evaluation. For all specimen types, submitted blocks should have sufficient tissue to generate at least 15 sections, and each section should contain at least 100 viable tumor cells.
- •c.Fine-needle aspiration (defined as samples that do not preserve tissue architecture and yield cell suspension and/or cell smears), brushing, cell pellet from pleural effusion, and lavage samples are not acceptable.
- •d.Tumor tissue from bone metastases that have been decalcified is not acceptable.
- •10.Willing and able to provide blood samples prior to the start of this study.
排除标准
- •1.For Part 2 and Part 4 with BDC 1001 and nivolumab combination therapy:
- •a.Patient has a history of immune-mediated colitis
- •b.Patient has an active autoimmune disease with the exception of autoimmune endocrinopathies that are stable on hormone replacement therapy
- •c.History of allergy or hypersensitivity to nivolumab components
- •d.History of life-threatening toxicity related to prior immune therapy (eg, anti-CTLA-4 or anti-PD-1/ PD L1 treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) except those that are unlikely to re-occur with standard countermeasures (eg, Hypothyroidism)
- •2.Cardiovascular exclusions:
- •a.Has a medical history of symptomatic congestive heart failure (New York Heart Association classes II IV) or a cardiac arrhythmia that requires treatment
- •b.Has a medical history of myocardial infarction or unstable angina within 6 months before C1D1
- •c.Has a mean QTcF prolongation of > 450 milliseconds (ms) in males and > 470 ms in females based on a 12 lead electrocardiogram (ECG) in triplicate
- •d.Has a medical history of an arterial thrombotic event, stroke, or transient ischemia attack within the past 12 months
- •3.Other exclusions:
- •a.History of treatment with a toll-like receptor (TLR)7, TLR8, or TLR7/8 agonist
- •b.Patient was previously enrolled in this study
- •c.Actively enrolled in another clinical study, unless it is an observational (noninterventional) clinical study or the follow-up component of an interventional study
- •d.Use of another investigational agent or anticancer therapy within 4 weeks prior to C1D1 or within 5 estimated elimination half-lives, whichever is shorter
- •e.Treatment with complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks prior to first study treatment.
- •f.Use of another anti-HER2 therapy within 4 weeks prior to C1D1
- •g.Use of strong inducers or inhibitors of major human cytochrome P450 (CYP) isoenzymes and transporters within 2 weeks prior to C1D1
- •h.History of severe hypersensitivity to any ingredient of BDC-1001, including trastuzumab.
- •i.Recent medical concerns and exclusions:
- •i.Patient has evidence of active infection and is being treated with intravenous (IV) therapy within 7 days prior to C1D1
- •ii.Radiation therapy within 2 weeks of C1D1
- •iii.Patient has active uncontrolled bleeding, or a bleeding diathesis within 7 days prior to C1D1
- •iv.Patient has an infected wound, fistula, skin ulcer, or non-healing bone fracture within 7 days prior to C1D1
- •v.Patient is a lactating mother or pregnant as confirmed by pregnancy tests within 7 days prior to C1D1
- •vi.Patient has had a live/attenuated virus vaccine within 30 days prior to C1D1
- •vii.Active SARS-CoV-2 infection as determined by viral testing.
- •viii.Prior history of pneumonitis (contact Medical Monitor)
- •4.Patient has known human immunodeficiency virus (HIV) infection (by antibody test), active hepatitis B infection (by hepatitis B surface antigen [HbsAg] test), or hepatitis C infection (by antibody test followed by confirmatory RNA test if antibody test is positive)
- •5.Patient is unwilling to use adequate contraceptive methods (as per Inclusion Section 4.1)
- •6.Patient has untreated central nervous system or brain metastasis
- •7.Patient taking steroids exceeding 10 mg/day prednisone for a corticosteroids or equivalent dose. Inhaled, intranasal, intraocular, topical, and intraarticular joint injections of corticosteroids are allowed.
研究者
相似试验
未知
1 期
Phase I Study of GDC-0068 as a Single Agent and in Combination with Other Anticancer Drugs in Patients with Advanced Solid Tumors.JPRN-jRCT2080222858CHUGAI PHARMACEUTICAL CO., LTD30
已完成
1 期
A phase 1 clinical trial of BDCA-BDC-01, a BDC-1 blood dendritic cell preparation loaded with control and tumour-associated antigens to evaluate the safety of immune therapy in metastatic hormone refractory prostate cancerMetastatic hormone refractory prostate cancerCancer - ProstateACTRN12605000130662Mater Medical Research Institute12
未知
1 期
PHASE I STUDY OF GDC-0919 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTICANCER DRUGS IN PATIENTS WITH ADVANCED SOLID TUMORSJPRN-jRCT2080223275CHUGAI PHARMACEUTICAL CO., LTD.42
进行中（未招募）
1 期
A study evaluating single-agent inavolisib and inavolisib plus atezolizumab in PIK3CA-mutated cancersPIK3CA-mutated solid cancers including previously treated recurrent or metastatic HNSCCCancerISRCTN11595117F. Hoffmann-La Roche Ltd40
尚未招募
2 期
A study of effectiveness of chemotherapeutic agent Pemetrexed in previously treated ovarian or primary peritoneal cancerCTRI/2022/08/044939Dr BRA IRCH AIIMS New Delhi